This trial will offer men with intermediate risk prostate cancer the opportunity to be randomized between low dose rate brachytherapy and high dose rate brachytherapy. Men will also be offered the opportunity to test the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.
1 Primary · 7 Secondary · Reporting Duration: 5-10 years
60 Total Participants · 2 Treatment Groups
Primary Treatment: High Dose Rate prostate brachytherapy · No Placebo Group · Phase 3
Age 40 - 80 · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: